• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    NSM Named Exclusive Distributor of Ekso Indego® Personal Within the CRT Industry

    2/10/25 7:00:00 AM ET
    $EKSO
    Industrial Machinery/Components
    Industrials
    Get the next $EKSO alert in real time by email

    SAN RAFAEL, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has named National Seating & Mobility ("NSM"), a leading provider of complex rehabilitation technology ("CRT"), mobility and accessibility solutions, as the Company's exclusive Ekso Indego® Personal device distributor within the CRT industry in the United States.

    Ekso Indego Personal is a wearable lower extremity powered exoskeleton that enables certain individuals living with spinal cord injuries ("SCIs") with the ability to stand and walk independently. It is the only known portable exoskeleton device to offer a modular quick connect design, which was engineered to allow users to put on and take off the device without assistance. Ekso Indego Personal is the lightest known commercial exoskeleton available offering ease of handling, transportation, and storage. Also offering an advanced gait mode, individuals with a SCI using the device have been shown to reach faster walking speeds, granting them a new level of independence in the community.

    "We are excited to expand the distribution of the Ekso Indego Personal device through this strategic commercial partnership with NSM," commented Scott Davis, the Company's Chief Executive Officer. "Both companies see a world where people have widespread access to innovative technologies that allow them to rethink their current physical limitation. We are looking forward to working with NSM to make that a reality. And as a fast-growing, well-established company in the CRT space, NSM's proven expertise and robust infrastructure are well aligned with our growth strategy."

    "NSM is committed to investing in resources and partnerships that enable us to bring the most advanced mobility and accessibility solutions to those we serve," said Crispin Teufel, CEO of NSM. "We are proud to partner with Ekso Bionics to expand access to the life-changing Ekso Indego device to those who rely on CRT equipment and can benefit from the mobility and therapy this innovative technology provides."

    "We will apply both our expertise in providing one-of-a-kind mobility technologies for individuals with various conditions, and our experience with insurance submissions through our vast panel of insurance partners, to help bring Ekso Indego Personal to more people who could benefit from standing and walking in addition to wheeled mobility," added Mr. Teufel.

    About Ekso Bionics®

    Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Founded in 2005, the Company continues to build upon its industry-leading expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only known exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. The Company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol "EKSO." For more information, visit: www.eksobionics.com or follow @EksoBionics on X.

    About National Seating & Mobility

    With a network of 180+ locations across the U.S. and Canada, National Seating & Mobility (NSM) is North America's largest and most trusted provider of comprehensive mobility solutions including complex rehab technology (CRT), home and vehicle accessibility, and full-service maintenance and repair. NSM has been advancing independence and enhancing the quality of life of individuals who use mobility solutions for more than 30 years. The company has more than 2,400 dedicated team members who support more than 250,000 mobility solutions each year. Since 2006, NSM is the only national mobility solutions provider that is accredited by The Joint Commission and voluntarily undergoes a rigorous review process every few years to ensure and validate the company's commitment to providing safe, quality care for our valued customers. For more information visit www.nsm-seating.com.

    Forward-Looking Statements

    Any statement contained in this press release that does not describe historical facts may constitute a forward-looking statement. Forward-looking statements may include, without limitation, statements regarding the ability of National Seating & Mobility to distribute the Company's Ekso Indego Personal device within the complex rehabilitation technology industry in the United States, and the Company's ability to bolster demand for its technology and execute on its long-term growth strategy. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund and grow the Company's operations and to develop or enhance the Company's technology, the Company's inability to obtain future reimbursements from CMS in a timely manner and at the expected reimbursement levels, the Company's inability to obtain insurance coverage beyond CMS, the Company's inability to obtain additional indications of use for its devices, any delay or discontinuation of the sales and distribution of Esko Indego Personal within the complex rehabilitation technology industry, or Ekso Indego Personal risks related to product liability, recall and warranty claims. These and other factors are identified and described in more detail in the Company's filings with the U.S. Securities and Exchange Commission. To learn more about Ekso Bionics please visit the Company's website at www.eksobionics.com or follow @EksoBionics on X. The Company does not undertake to update these forward-looking statements, except as required by law.

    Contact:

    Stephen Kilmer

    Investor Relations

    Direct: (646) 274-3580

    Email: [email protected]



    Primary Logo

    Get the next $EKSO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EKSO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $EKSO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ekso Bionics Accepted into NVIDIA Connect Program

      Company unveils a strategic initiative to build the world's first known foundation model for human motion in physical rehabilitation Collaboration represents an important step toward integrating powerful new AI capabilities into Ekso Bionics' proprietary exoskeleton technology platforms SAN RAFAEL, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced its acceptance into the NVIDIA Connect program. The Company plans to use the valuable tools and resources provided through this prestigious NVIDIA program to support a new strategic

      5/15/25 7:45:00 AM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Ekso Bionics Reports First Quarter 2025 Financial Results

      SAN RAFAEL, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended March 31, 2025. Recent Highlights and Accomplishments Strengthened financial position by improving operating cash burn by 43% combined with $3.8 million in net proceeds from the exercise of warrantsNamed National Seating & Mobility ("NSM") as its exclusive Ekso Indego® Personal device distributor within the U.S. complex rehabilitation technology ("CRT") industryNamed Bionic Prosthetics & Orthotics Group ("Bionic P&O") as its

      5/5/25 4:05:00 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Ekso Bionics to Report First Quarter 2025 Financial Results on May 5 – Conference Call to Follow

      SAN RAFAEL, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter of 2025 after the close of trading on Monday, May 5, 2025. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to review the financial results and discuss recent business developments. To participate in the conference call by telephone, please dial 877-407-6184 (domestic) or 201-389-0877 (international). The call will also be broadcast live and archived on the Company's website at www.

      4/28/25 4:30:00 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials

    $EKSO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Wong Jerome was granted 24,248 shares (SEC Form 4)

      4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

      3/18/25 6:07:04 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Chief Operating Officer Jones Jason C was granted 24,248 shares (SEC Form 4)

      4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

      3/18/25 6:06:43 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • CEO Davis Scott G. was granted 5,590 shares (SEC Form 4)

      4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

      3/18/25 6:06:18 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials

    $EKSO
    Financials

    Live finance-specific insights

    See more
    • Ekso Bionics Reports First Quarter 2025 Financial Results

      SAN RAFAEL, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended March 31, 2025. Recent Highlights and Accomplishments Strengthened financial position by improving operating cash burn by 43% combined with $3.8 million in net proceeds from the exercise of warrantsNamed National Seating & Mobility ("NSM") as its exclusive Ekso Indego® Personal device distributor within the U.S. complex rehabilitation technology ("CRT") industryNamed Bionic Prosthetics & Orthotics Group ("Bionic P&O") as its

      5/5/25 4:05:00 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Ekso Bionics to Report First Quarter 2025 Financial Results on May 5 – Conference Call to Follow

      SAN RAFAEL, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter of 2025 after the close of trading on Monday, May 5, 2025. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to review the financial results and discuss recent business developments. To participate in the conference call by telephone, please dial 877-407-6184 (domestic) or 201-389-0877 (international). The call will also be broadcast live and archived on the Company's website at www.

      4/28/25 4:30:00 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Ekso Bionics Reports Fourth Quarter and Full-Year 2024 Financial Results

      SAN RAFAEL, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2024. Recent Highlights and Accomplishments Record Q4-2024 revenue of $5.1 millionQ4-2024 gross margin increased 400 basis points year-over-year to 53%Subsequent to year-end, Company named National Seating & Mobility as its exclusive Ekso Indego® Personal device distributor within the U.S. complex rehabilitation technology (CRT) industry "We are pleased to close out 2024 with recor

      3/3/25 4:05:00 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials

    $EKSO
    SEC Filings

    See more
    • SEC Form 10-Q filed by Ekso Bionics Holdings Inc.

      10-Q - EKSO BIONICS HOLDINGS, INC. (0001549084) (Filer)

      5/5/25 4:08:10 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Ekso Bionics Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - EKSO BIONICS HOLDINGS, INC. (0001549084) (Filer)

      5/5/25 4:06:47 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • SEC Form 11-K filed by Ekso Bionics Holdings Inc.

      11-K - EKSO BIONICS HOLDINGS, INC. (0001549084) (Filer)

      4/18/25 4:25:35 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials

    $EKSO
    Leadership Updates

    Live Leadership Updates

    See more
    • Ekso Bionics Accepted into NVIDIA Connect Program

      Company unveils a strategic initiative to build the world's first known foundation model for human motion in physical rehabilitation Collaboration represents an important step toward integrating powerful new AI capabilities into Ekso Bionics' proprietary exoskeleton technology platforms SAN RAFAEL, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced its acceptance into the NVIDIA Connect program. The Company plans to use the valuable tools and resources provided through this prestigious NVIDIA program to support a new strategic

      5/15/25 7:45:00 AM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Ekso Bionics Appoints Deborah Lafer Scher to its Board of Directors

      Brings Strategic Healthcare Expertise and Extensive Experience with the U.S. Department of Veterans Affairs (VA) to Ekso's Board Deborah Lafer Scher SAN RAFAEL, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced the appointment of Deborah Lafer Scher to its Board of Directors, effective June 6, 2024. "We are pleased to strengthen our Board with the addition of Deborah Lafer Scher, a distinguished leader who brings a wealth of healthcare experience and a proven track record of business development expertise," said Scott Davis, President and Chie

      6/17/24 4:05:00 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Ekso Bionics Announces Acquisition of Human Motion and Control Business Unit Including Indego® Product Line From Parker Hannifin Corporation

      Broadens Ekso Bionics' product portfolio into home use Adds Vanderbilt University as a key commercial and research partner Acquisition consolidates leading lower extremity robotic companies Ekso President and COO Scott Davis promoted to Chief Executive Officer; Steven Sherman to remain Chairman, appointed Executive Chair SAN RAFAEL, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced the acquisition of the Human Motion and Control ("HMC") Business Unit from Parker Hannifin Corporation ("Parker"), a global leader in motion and control technologies. The acquisiti

      12/5/22 8:37:01 AM ET
      $EKSO
      Industrial Machinery/Components
      Industrials

    $EKSO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Ekso Bionics Holdings Inc.

      SC 13G - EKSO BIONICS HOLDINGS, INC. (0001549084) (Subject)

      11/14/24 3:29:01 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13G/A filed by Ekso Bionics Holdings Inc. (Amendment)

      SC 13G/A - EKSO BIONICS HOLDINGS, INC. (0001549084) (Subject)

      2/11/22 6:17:59 AM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13G filed

      SC 13G - EKSO BIONICS HOLDINGS, INC. (0001549084) (Subject)

      2/12/21 10:16:25 AM ET
      $EKSO
      Industrial Machinery/Components
      Industrials

    $EKSO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lathan Corinna bought $15,477 worth of shares (13,733 units at $1.13), increasing direct ownership by 10% to 147,990 units (SEC Form 4)

      4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

      3/14/24 6:41:52 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials